Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4888)	11/6/2001 2:00:20 PM
From: NeuroInvestment	Read Replies (1) \| Respond to of 52153

Peter: As you may have heard on the CC, the numbers they threw around for Provigil use were: Narcolepsy 30-35% Sleep apnea 10% MS fatigue 15-20% Depression 30-35% I believe it is depression that is really driving the off-label sales, and CEPH's own estimates indicate depression sales now equal on-label sales. Historically, Ritalin has with some frequency been used by psychiatrists to give a 'jump-start ' to depressed patients waiting three weeks for a tricyclic or SSRI to kick in. Provigil gives them a less problematic option for a mild 'stimulant'--and gives a depressed patient the feeling something is happening, when three weeks feels like forever. That is why Cephalon is really pushing its psychiatry sales. BTW--I know a number of MDs who, in the difficult days after Sept. 11, used their samples of Provigil on themselves to keep going after several nights of disrupted sleep. Harry Tracy NeuroInvestment www.neuroinvestment.com